These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25101665)

  • 1. Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).
    Burza S; Mahajan R; Sinha PK; van Griensven J; Pandey K; Lima MA; Sanz MG; Sunyoto T; Kumar S; Mitra G; Kumar R; Verma N; Das P
    PLoS Negl Trop Dis; 2014 Aug; 8(8):e3053. PubMed ID: 25101665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India.
    Burza S; Sinha PK; Mahajan R; Lima MA; Mitra G; Verma N; Balasegaram M; Das P
    PLoS Negl Trop Dis; 2014; 8(1):e2603. PubMed ID: 24392168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
    Abongomera C; Diro E; de Lima Pereira A; Buyze J; Stille K; Ahmed F; van Griensven J; Ritmeijer K
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006527. PubMed ID: 29799869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India.
    Burza S; Sinha PK; Mahajan R; Lima MA; Mitra G; Verma N; Balasegaram M; Das P
    PLoS Negl Trop Dis; 2014; 8(1):e2536. PubMed ID: 24392166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
    Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
    PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
    Sinha PK; van Griensven J; Pandey K; Kumar N; Verma N; Mahajan R; Kumar P; Kumar R; Das P; Mitra G; Flevaud L; Ferreyra C; Remartinez D; Pece M; Palma PP
    Clin Infect Dis; 2011 Oct; 53(7):e91-8. PubMed ID: 21890763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?
    Salih NA; van Griensven J; Chappuis F; Antierens A; Mumina A; Hammam O; Boulle P; Alirol E; Alnour M; Elhag MS; Manzi M; Kizito W; Zachariah R
    Trop Med Int Health; 2014 Feb; 19(2):146-52. PubMed ID: 24433217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.
    Mahajan R; Das P; Isaakidis P; Sunyoto T; Sagili KD; Lima MA; Mitra G; Kumar D; Pandey K; Van Geertruyden JP; Boelaert M; Burza S
    Clin Infect Dis; 2015 Oct; 61(8):1255-62. PubMed ID: 26129756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
    Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
    Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial.
    Burza S; Mahajan R; Kazmi S; Alexander N; Kumar D; Kumar V; Lasry E; Harshana A; de Lima Pereira A; Das P; Verma N; Das VNR; Lal CS; Rewari B; Goyal V; Rijal S; Alves F; Gill N; Pandey K
    Clin Infect Dis; 2022 Oct; 75(8):1423-1432. PubMed ID: 35147680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
    Goyal V; Das VNR; Singh SN; Singh RS; Pandey K; Verma N; Hightower A; Rijal S; Das P; Alvar J; Bern C; Alves F
    PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008429. PubMed ID: 32687498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does timing of antiretroviral treatment influence treatment outcomes of visceral leishmaniasis in Northwest Ethiopia?
    Aderie EM; Diro E; Zachariah R; da Fonseca MS; Abongomera C; Dolamo BL; Ritmeijer K
    Trans R Soc Trop Med Hyg; 2017 Mar; 111(3):107-116. PubMed ID: 28633331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh.
    Lucero E; Collin SM; Gomes S; Akter F; Asad A; Kumar Das A; Ritmeijer K
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003699. PubMed ID: 25837313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
    Diro E; Blesson S; Edwards T; Ritmeijer K; Fikre H; Admassu H; Kibret A; Ellis SJ; Bardonneau C; Zijlstra EE; Soipei P; Mutinda B; Omollo R; Kimutai R; Omwalo G; Wasunna M; Tadesse F; Alves F; Strub-Wourgaft N; Hailu A; Alexander N; Alvar J
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006988. PubMed ID: 30653490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmania-HIV co-infection: clinical presentation and outcomes in an urban area in Brazil.
    Cota GF; de Sousa MR; de Mendonça AL; Patrocinio A; Assunção LS; de Faria SR; Rabello A
    PLoS Negl Trop Dis; 2014 Apr; 8(4):e2816. PubMed ID: 24743472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved kala-azar case management through implementation of health facility-based sentinel sites surveillance system in Bihar, India.
    Das VNR; Siddiqui NA; Bhunia GS; Pandey K; Sinha SK; Ansari MZ; Topno RK; Lal CS; Ranjan A; Singh VP; Das P
    PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009598. PubMed ID: 34428232
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    van Griensven J; Mengesha B; Mekonnen T; Fikre H; Takele Y; Adem E; Mohammed R; Ritmeijer K; Vogt F; Adriaensen W; Diro E
    Front Cell Infect Microbiol; 2018; 8():94. PubMed ID: 29651411
    [No Abstract]   [Full Text] [Related]  

  • 19. Pre- & post-treatment evaluation of immunological features in Indian visceral leishmaniasis (VL) patients with HIV co-infection.
    Sinha PK; Bimal S; Singh SK; Pandey K; Gangopadhyay DN; Bhattacharya SK
    Indian J Med Res; 2006 Mar; 123(3):197-202. PubMed ID: 16778304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia.
    Diro E; Edwards T; Ritmeijer K; Fikre H; Abongomera C; Kibret A; Bardonneau C; Soipei P; Mutinda B; Omollo R; van Griensven J; Zijlstra EE; Wasunna M; Alves F; Alvar J; Hailu A; Alexander N; Blesson S
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007132. PubMed ID: 30789910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.